Introduction
============

Accurate prediction of SNV impact is an important challenge
-----------------------------------------------------------

Since making its first clinical diagnosis in 2009,[@b1] whole exome sequencing has been on the rise for both individual patient diagnosis and large-scale projects, in keeping with decreasing production costs ([Fig. 1](#fig01){ref-type="fig"}). Our capacity to obtain sequencing information has expanded so quickly that it now far out-paces Moore\'s doubling law for computing power.[@b5] Whereas targeted gene sequencing and Genome Wide Association Studies (GWAS) at predetermined loci used to be the cutting edge,[@b6],[@b7] new studies aim to identify single nucleotide variations (SNVs) in all genes and to analyze their association with disease.[@b8] There are now thousands of sequenced exomes encompassing phenotypes both rare (e.g., Joubert syndrome,[@b9] myofibrillar myopathy[@b10]), and relatively common (e.g., cancer[@b11]--[@b16] and epilepsy[@b17],[@b18]). Many of these exome projects have been catalogued and made available for analysis through the Database of Genotypes and Phenotypes (dbGaP),[@b19],[@b20] and multi-center efforts like the NHLBI Exome Sequencing Project[@b21] are actively gathering more data. With this influx of information, researchers are now limited not by a lack of material, but instead by the challenges of processing and interpreting this wealth of information. With more candidate SNVs to evaluate than ever before, accurate methods that predict the effect of SNVs are crucial to ensure that research focuses on those variations that are most likely to cause disease.

![Production cost and usage of whole exome sequencing over time. As the cost of exome sequencing (blue) decreases, the number of articles containing the phrase "whole exome sequencing" (red) increases. The number of articles is found via Scopus.[@b2] The production cost is defined by the National Human Genome Research Institute[@b3] and includes the costs of labor, sequencing instruments, and data processing, but not quality control, technology development, or data analysis. As of April 2014, the production cost for an exome on the Illumina or SOLiD platform at 30-fold coverage was \$49.20, although the actual cost to the consumer is considerably higher, with costs advertised in the range of \$700 to \$2000 per sample.[@b4]](pro0023-1650-f1){#fig01}

Most tools focus on coding SNVs rather than other SNVs
------------------------------------------------------

Decoding the relationship between genotype and phenotype is a major challenge in genetics. In humans there are more than four million DNA differences between two random individuals.[@b22],[@b23] Because additions and deletions typically have stronger impact,[@b24]--[@b26] and are selected against more often, ∼80% of these differences are single nucleotide variations (SNVs).[@b27]--[@b29] Over the entire human population, an estimated 81%[@b30] to 93%[@b31] of human genes contain at least one SNV. Although only a small fraction of variants are non-synonymous single nucleotide variations (nsSNVs), about 10,000 are found between two random individuals,[@b27]--[@b29] and over 85% of known disease associations are culled from this important class of mutations.[@b1] For this reason, methods for predicting the impact of SNVs have historically focused on the high-yield category of non-synonymous coding SNVs. The existence of disease-associated synonymous mutations[@b32],[@b33] and nocoding variations with effects on lincRNA,[@b34] miRNA,[@b35],[@b36] and promoters[@b37],[@b38] has produced interest in other types of mutations as well, but different tools will be needed to analyze these types of variations and such tools are comparatively still new and untested.[@b39]--[@b41]

Most nsSNVs affect protein function but in distinct ways
--------------------------------------------------------

nsSNVs may affect folding,[@b42],[@b43] binding affinity,[@b44],[@b45] expression,[@b46] post-translational modification,[@b47],[@b48] and other protein features. However, not all nsSNVs impact protein function. Some variations may produce no perceivable changes to the protein, in which case the mutation may not be pathogenic. On the other hand, purifying selection should eliminate over time the mutations that are most deleterious to fitness. A telltale signal is a decreased ratio of non-synonymous to synonymous mutations compared to a model of neutral mutation theory.[@b49] Importantly, not all non-synonymous mutations are under the same strength of purifying selection. An analysis of exomes from the 1000 Genomes Project,[@b50] in accordance with simulations[@b51] and with Fisher\'s geometric model[@b52] showed that the number of the nsSNVs retained in the human population decreases exponentially as the impact on fitness increases. The same analysis also showed that the exponential decrease becomes steeper for nsSNVs with higher allelic frequency, reflecting that the more common mutations have been selected against stronger constraints. This demonstrates the complexity of the genotype-to-phenotype relationship and implies that a binary classification of a mutation into deleterious or neutral, although very convenient, may be too simplistic.[@b53]

Goal of the review
------------------

Predictors of the impact of nsSNVs are useful for associating variants to phenotypic traits and diseases, but they should be used cautiously and with an understanding of the benefits and pitfalls of using each method. However, researchers attempting to understand the field may feel overwhelmed by the plethora of available predictors to consider. Here we classify current predictors of functional impact by their underlying theory and we discuss the fundamental principles, assumptions, strengths, and limitations of each type of method. Finally, we speculate on the future directions of variant prioritization and review applications for nsSNV impact prediction in guided mutagenesis studies, the identification of disease-causing nsSNVs, the association of genes to diseases, and the prediction of polygenic phenotypes from whole exome data.

Predicting SNV Impact
=====================

While many features have been used to predict the impact of nsSNVs, there are two major features that are commonly used in bioinformatics tools: structure and sequence homology.

Structural metric of nsSNV impact
---------------------------------

Some of the first methods to predict the impact of nsSNVs were based solely on structure.[@b54],[@b55] They assumed that deleterious nsSNVs destabilize the folding of proteins and therefore aimed to estimate the free energy change of folding (ΔΔ*G*) due to a mutation. Roughly three quarters of amino acid substitutions that result in Mendelian diseases do affect protein stability, proving the value of this assumption.[@b56],[@b57] Impacting protein stability typically implies local or total unfolding of the protein, but occasionally deleterious aggregates like amyloid fibrils[@b58],[@b59] may form. Rarely, single mutations have been known to cause a switch between stable folds.[@b60] To avoid the computational expense of physical models like Molecular Dynamics simulations, most methods use statistical (PopMuSiC-2.0,[@b61] SDM[@b54]) or empirical (FoldX/SNPeffect,[@b62],[@b63] Dmutant[@b55]) effective energy functions. These methods typically require a structure for the region of the protein under investigation, although some methods can use sequence information alone.[@b64] Originally, SDM, a knowledge-based approach, used environment-dependent amino acid substitution with propensity tables and considered a structure\'s main-chain conformations, solvent accessibilities, hydrogen bonds, and disulfide bonds.[@b54] Later methods used this information to help calculate basic potentials, low-order and high-order coupling terms, volume terms, and solvent accessibility terms for comprehensive scoring functions that can be weighted through training with machine learning techniques[@b61] or direct fitting to empirical data.[@b63],[@b65] Other structural components that are taken into account include small-molecule binding sites, protein--protein interactions, entropy optimization, and Van der Waals and torsional clashes.[@b63],[@b66]

These structure-based methods give insight about the local environment of the mutation. Variants on the surface are, in general, more likely to be neutral than variants in the core,[@b67] indicating that disease-associated mutations often affect intrinsic structural features of proteins.[@b68] However, surface mutations at important protein--protein interaction sites are more likely to be disease-associated.[@b69] Using the structure also has the advantage of accounting for the interactions between amino acid residues that are close in three-dimensional space but far apart in the protein\'s sequence. Loss or gain of disulfide, electrostatic or hydrophobic interactions that affect protein stability or aggregation are examples of interaction changes that the use of 3-D structure can help identify.[@b70],[@b71]

Unfortunately, even with a deposition rate outpacing PubMed article submission[@b72] and after recently reaching the milestone of 100,000 structures,[@b73] it is still a relatively small fraction of all proteins that can be found in the protein data bank. For example, in a recent study on epilepsy disorders[@b66] only 18/68 of the proteins of interest had partial structures. For the remaining proteins, only 22% of the mutations could be mapped onto a predicted structure from theoretical models based on homology of known structures.[@b66] For a larger perspective, only 7.6% of 57,525 nsSNVs from the Humsavar database could be mapped to structures.[@b74] This percentage increased to 60.4% when Phyre2 homology models[@b75] were included,[@b74] but still the proportion of unaddressed SNVs was large. Another pitfall is that the PDB may contain structures, often flagged with a warning,[@b76] that have unresolved concerns regarding geometry, stereochemistry, or solvent, and that contribute to inconsistency in the quality of the available structures.[@b77] Overall, structural information has its greatest value in nsSNV impact prediction in cases where a complete and robust protein structure is available and where the protein has few homologs, compromising the prediction accuracy of methods that rely heavily on homology.[@b78],[@b79]

Evolutionary metrics of nsSNV impact
------------------------------------

A complementary approach to determine the impact of nsSNVs is based on evolutionary principles. At first, substitution matrices like BLOSUM62[@b80] were used to classify a nsSNV as impactful or not[@b81] by the similarity of an amino acid substitution as judged by the interchanges between homologous proteins. This type of substitution matrix was originally designed for database searching and pairwise alignment[@b82] and then repurposed to predict nsSNV impact. When used as a standalone prediction tool, BLOSUM62 matrices over-predict non-conservative substitutions,[@b83] and many early methods demonstrated their feasibility by showing improvements in accuracy over BLOSUM62 predictions.[@b83],[@b84] While BLOSUM62 uses a non-specific substitution profile, many homology-based methods now assess amino acid substitution profiles in a more sophisticated and family specific manner.

Homology-based methods typically assume that the overrepresented substitutions in a protein family are neutral on protein function and that the underrepresented ones are deleterious[@b25],[@b83],[@b84] ([Fig. 2](#fig02){ref-type="fig"}). This implies two hypotheses: that each substitution has an independent effect on protein function (no epistasis) and that all homologs have identical function (the fitness landscape is constant).[@b83],[@b84] The prediction accuracy is significantly affected upon violation of these hypotheses and most methods attempt to minimize this problem by optimizing the sequence selection to mostly orthologous proteins, thereby minimizing changes in the fitness landscape.[@b25] Although non-native alignments can sometimes improve the accuracy of a method,[@b85] customizing the sequence alignment in a rational way requires a great deal of knowledge and finesse.

![TP53 sequences from different species and variations in their amino acids. Some homology-based methods would predict that the human sequence would tolerate a substitution of alanine to aspartic acid or to cysteine at the highlighted position. Other methods account for the conservation of a position, concluding that the highlighted position would likely tolerate more substitutions than other positions.](pro0023-1650-f2){#fig02}

At the most basic level, the early homology methods (SIFT,[@b83] Panther[@b84]) judge the impact of nsSNVs by scoring the substitution frequency amongst homologues. To improve upon this simple principle, SIFT normalized the probabilities of all possible amino acid substitutions and Panther uses a Hidden Markov Model.[@b84] The next generation of methods (A-GVGD,[@b86] MAPP[@b87]) score the observed frequency of biochemical properties in each position of the alignment, such as the volume, polarity, hydropathy and charge, and how they differ from the properties of the substituted amino acid. These methods then conclude that a residue is deleterious for protein function when it does not comply with the protein family\'s substitution profile.[@b86],[@b87]

More recent implementations of homology have combined homology information together with substitution matrices. Provean uses an alignment-based score that measures the change in sequence similarity of the query sequence with each of its homologs, before and after the introduction of the mutation.[@b25] The similarity is estimated by using the BLOSUM62 matrix, and it can provide predictions for multiple amino acid substitutions, insertions, and deletions. Alternatively, the Evolutionary Action method models the genotype-to-phenotype relationship with an equation stating that the impact of a mutation is a product of the functional importance of the mutated residue and of the amino acid similarity of the substitution.[@b50] The functional importance is approximated by the Evolutionary Trace method[@b88],[@b89] and the amino acid similarity by substitution matrices that depend on the functional importance of the residues and optionally on their structural features. Overall, the abundance of such methods highlights the ability of homology to accurately predict the impact of nsSNVs independently from other features.

Homology has been a steadfast component of nsSNV impact prediction, whether by itself or in combination with structural information, but there are several limitations to its predictive power. In particular, the lack of available homologous sequences may result in lower prediction accuracy.[@b87] For example, the Provean method uses 100--200 homologous sequences on average, but when their number drops below 50, the accuracy is lower.[@b25] Another caveat is that the selection of sequences must be balanced to represent sufficiently deep evolution of the protein family without being biased to distant phylogenetic branches that have evolved to retain functions that are specific only to that branch. When the Provean method was tested on sequence alignments derived by using the UniProtKB/Swiss-Prot instead of the NCBI NR database, the accuracy dropped by 7% and this was attributed to the lack of orthologous and distantly related sequences.[@b25] Furthermore, the choice of the alignment has a major effect on the accuracy of a method. When each of four alignments was used as input to SIFT, A-GVGD, PolyPhen-2, and Xvar (now MutationAssessor), their accuracy varied widely, with A-GVGD being extremely sensitive to, and PolyPhen-2 being more robust to, changes in alignment.[@b85] Interestingly, the native alignments of each method did not necessarily give the best predictions for that method.[@b85] Overall, sequence homology can be applied to nsSNV impact prediction with great success if there are sufficient homologues in broad and deep branches of the phylogeny.

Integrative machine learning approaches
---------------------------------------

Several methods predict the impact of nsSNVs using both structure and homology, along with other types of information such as function annotation and biochemical properties. To combine key features, these methods use supervised machine learning techniques that integrate disparate data types through nonlinear relationships and handle outliers and noise more readily than linear approaches.[@b64] Supervised learning requires training with large numbers of known phenotype associations in order to deduce these complex relationships.[@b64],[@b90],[@b91] Ultimately, they classify the data into categories[@b91] like deleterious or neutral, and they may provide a confidence score for each prediction. Commonly used machine learning techniques include Support Vector Machines,[@b5],[@b64],[@b71],[@b92]--[@b96] Naive Bayes,[@b97],[@b98] Neural Networks,[@b90],[@b99] Random Forests,[@b100],[@b101] and Decision Trees.[@b93],[@b102]

Perhaps the most well-known impact predictor that uses machine-learning is PolyPhen2, which uses a naive Bayes classifier on substitution events in homologs, structural parameters, function annotation, and physicochemical features.[@b98] Typical training features include amino acid substitution profiles or homology derived scores,[@b71],[@b94],[@b98] biophysical properties of the substitution (volume,[@b71],[@b92],[@b98] hydropathy,[@b71],[@b92],[@b94] and charge[@b71],[@b92],[@b94]), structure information (secondary structure,[@b94] solvent accessibility,[@b92],[@b98] and crystallographic B-factors[@b98]), function annotation,[@b92],[@b98],[@b103] local environment information (neighbors in sequence or space),[@b64],[@b93],[@b94],[@b104] statistical potentials,[@b64] aggregation property,[@b62],[@b105] and intrinsically disordered regions.[@b105] Recently, SuSPect[@b74] even incorporated a network of protein-protein interactions from the STRING database[@b106] into its analysis.

Machine learning methods aim to identify and use non-redundant features that are highly correlated to accurate classification.[@b107] However, optimizing the selection of features may cause predictions to be less accurate for those proteins dependent on "atypical" features. For example, disruption of intrinsic disorder, a rarely used feature, is critical for predicting the impact of mutations in the tumor suppressor APC.[@b108] Determining which features contain the most relevant information and the least amount of noise has been a constant challenge, and several methods integrate predictions of existing methods with other methods (Condel),[@b109] or with additional features, (SNAP[@b99] and MutPred[@b110]), in order to increase the accuracy. At the publication time of this review, there is no consensus for a "best" set of features to predict the impact of SNVs, with different combinations working for different methods and datasets. The features considered by each method are detailed in Supporting Information Table[1](#tbl1){ref-type="table"}.

###### 

SNP Impact Predictors

  Server                     Year   Input                                                            URL                                                                                            Pubmed ID
  -------------------------- ------ ---------------------------------------------------------------- ---------------------------------------------------------------------------------------------- -----------
  Structural                                                                                                                                                                                        
   SDM                       1997   PDB ID                                                           [http://www-cryst.bioc.cam.ac.uk/∼sdm/sdm.php](http://www-cryst.bioc.cam.ac.uk/~sdm/sdm.php)   9051729
   Dmutant                   2002   PDB ID                                                           <http://sparks.informatics.iupui.edu/hzhou/mutation.html>(Unavailable)                         12381853
   PoPMuSiC                  2009   PDB ID                                                           <http://dezyme.com/>                                                                           19654118
   SDS                       2014   \-                                                               Cannot automate                                                                                24795746
  Homology                                                                                                                                                                                          
   SIFT                      2001   Protein identifier, SNP IDs, or alignment                        <http://sift.jcvi.org/>                                                                        11337480
   Panther                   2003   Sequence                                                         <http://www.pantherdb.org/tools/csnpScoreForm.jsp>                                             12952881
   MAPP                      2005   Alignment and phylogenetic tree                                  <http://mendel.stanford.edu/SidowLab/downloads/MAPP/index.html>                                15965030
   A-GVGD                    2006   Alignment                                                        <http://agvgd.iarc.fr/agvgd_input.php>                                                         16014699
   mutationassessor (xvar)   2011   Protein identifier or chrom. location                            <http://mutationassessor.org/>                                                                 21727090
   Provean                   2012   Sequence or chrom. location                                      <http://provean.jcvi.org/index.php>                                                            23056405
   Evolutionary action       2014   Protein identifier                                               <http://mammoth.bcm.tmc.edu/EvolutionaryAction/>                                               
  Hybrid                                                                                                                                                                                            
   PolyPhen                  2002   Protein identifier or sequence                                   <http://genetics.bwh.harvard.edu/pph/>                                                         12202775
   LogR.E-value              2004   Site is down for maintenance                                     <http://lpgws.nci.nih.gov/cgi-bin/GeneViewer.cg>                                               14751981
   nsSNPAnalyzer             2005   Sequence (requires available PDB structure)                      <http://snpanalyzer.uthsc.edu/>                                                                15980516
   SNPeffect                 2005   Sequence, PDB ID, UniProt ID                                     <http://snpeffect.switchlab.org/menu>                                                          15608254
   LS-SNP                    2005   SNP, protein or pathway identifier                               <http://modbase.compbio.ucsf.edu/LS-SNP/>                                                      15827081
   MUpro                     2005   Protein sequence, structure (optional)                           [mupro.proteomics.ics.uci.edu](http://mupro.proteomics.ics.uci.edu)                            16372356
   pmut                      2005   Sequence (on demand version) or PDB ID (precalculated version)   <http://mmb2.pcb.ub.es:8080/PMut/>                                                             15879453
   PhD-SNP                   2006   Protein identifier or sequence                                   <http://snps.biofold.org/phd-snp/phd-snp.html>                                                 16895930
   SNPs3D                    2006   SNP identifier                                                   <http://www.snps3d.org/>                                                                       16551372
   Parepro                   2007   Alignment                                                        <http://www.mobioinfor.cn/parepro/index.htm>                                                   18005451
   SAPRED                    2007   Sequence and PDB files                                           <http://sapred.cbi.pku.edu.cn/> (Login required)                                               17384424
   Imutant 3.0               2007   Sequence or PDB ID                                               <http://gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi>                     18387208
   SNAP                      2007   Sequence                                                         <http://rostlab.org/services/snap/submit>                                                      17526529
   AUTO-MUTE                 2010   PDB ID                                                           <http://proteins.gmu.edu/automute/AUTO-MUTE_nsSNPs.html>                                       20573719
   Mutation Taster           2010   Transcript, gene, or ORF                                         <http://www.mutationtaster.org>                                                                20676075
   PolyPhen2                 2010   Protein or SNP identifier or sequence                            <http://genetics.bwh.harvard.edu/pph2/>                                                        20354512
   Condel                    2011   Protein identifier, mutation, homology tree                      No server, but can get PERL pipeline scripts and then download each tool                       21457909
   CADD                      2014   VCF file                                                         <http://cadd.gs.washington.edu/score>                                                          24487276
   VarMod                    2014   Sequence                                                         <http://www.wasslab.org/varmod/>                                                               24906884
   SuSPect                   2014   Sequence or VCF                                                  <http://www.sbg.bio.ic.ac.uk/suspect/index.html>                                               24810707

Another limitation of the machine learning methods is that they may rely on asymmetric training sets that may misrepresent population characteristics.[@b104] For example, if a Gaussian distribution was randomly sampled, one might obtain by chance a few more samples on one side of the curve (Supporting Information [Fig. 1](#fig01){ref-type="fig"}). Using this skewed distribution in a machine learning technique underfits the data and can cause false predictions defeating the purpose of the learning process.[@b91],[@b111] However, this "generalization error" can at least be minimized by mathematical models.[@b112] Equally problematic, if a method is over-trained on a dataset, noise will be built in and the performance of the model will drop.[@b91],[@b111],[@b112] Finally, using machine learning methods to predict the impact of mutations that differ fundamentally from the training data may require retraining and revalidating the tool. For example, using SuSPect, which was initially trained only on human SNVs, to predict the impact of mutations in non-human proteins dropped the AUC by about 10%.[@b74]

Availability and Comparisons
============================

A summary of well-known current methods to predict the impact of nsSNV is provided in Table[1](#tbl1){ref-type="table"}, and a more detailed version of this table exists in the Supporting Information Table[1](#tbl1){ref-type="table"}. The majority of these methods are freely available to the research community through web servers or through downloadable files for local use. Using them often requires basic to advanced bioinformatics skills, as presented in Karchin 2008.[@b113] At its most basic, a user has to input just an identifier of the protein of interest or its sequence, and in some cases the specific amino acid substitution as well. To better assist users, many methods allow submitting large number of prediction requests at a time, and others give an option to input user-curated sequence alignments of the protein family.

New tools determine their accuracy by applying their method to various sets of nsSNVs whose impact is known and measuring how well they are able to distinguish harmful mutations from benign ones. Ambitious mutagenesis work on a particular protein is one way these validation sets are developed. For example, 4041 mutations of the *E. coli* LacI protein,[@b114],[@b115] 336 mutations of HIV-1 protease,[@b116] 2015 mutations of bacteriophage T4 lysozyme,[@b117] and 2314 mutations of the human p53 protein[@b118] have been assayed for functional effect and catalogued. Many tools, including SIFT,[@b83] MutationAssessor,[@b65] Provean,[@b25] MAPP,[@b87] and EA,[@b50] compare to one or more of these classic datasets. Another type of validation set comes from reference human SNVs that have been classified as disease-associated variants (deleterious) or common polymorphisms (presumed benign). These datasets include VariBench,[@b119] HGMD,[@b120] and the "human polymorphisms and disease mutations" set available from the UniProtKB/Swiss-Prot database,[@b121] each of which contains tens of thousands of missense variants. This type of validation set has the advantage of being human-specific and encompassing many proteins, but relies on the accuracy of annotations in the databases and can only consider SNV impact in a binary fashion. On the other hand, validation sets from mutagenesis studies are more limited in scope but involve functional assays that consider impact on a continuous scale.

The performance of different methods to predict the impact of mutations is typically compared with the area under the curve (AUC) of the receiver operating characteristic (ROC) plots. An ROC plots the true positive rate against the false positive rate and demonstrates the trade-off between sensitivity and specificity. The AUC quantifies the success of this trade-off. A perfect prediction would result in a vertical line (infinite slope) at the origin and an AUC of 1, in contrast to a completely random prediction that would result in a line with a slope of 1 and an AUC of 0.5. Other measures to evaluate the ability of prediction methods to prioritize the impact of mutations include the balanced accuracy, which is the average of the sensitivity and specificity,[@b25] the F1 score, which is the harmonic mean of precision and recall,[@b122] the Matthews correlation coefficient (MMC),[@b93] the Spearman\'s rank correlation coefficient,[@b123] the Kendall tau rank correlation coefficient,[@b124] and the scale-dependent metric root-mean-square deviation (RMSD).[@b61]

It is important to be cautious when attempting to objectively compare methods, and only new, unpublished data should be included in a validation set in order to keep the methods on equal footing. Otherwise, machine learning methods that have used part of the validation data in their training may appear to be more accurate than they really are. When available, comparisons that are performed by independent researchers are preferable.[@b53],[@b85] In one such study, the performance of four commonly used methods (SIFT, Align-GVGD, PolyPhen-2, and Xvar which is now called MutationAssessor) was compared for 267 well-characterized human missense mutations in the BRCA1, MSH2, MLH1, and TP53 genes.[@b85] All four algorithms performed similarly, with an AUC of about 80%, but the predictions by each algorithm were often discordant even when each one was provided the same input alignment.[@b85] Thus, while these methods perform similarly in their overall accuracy, their predictions are different,[@b85] a phenomenon that is documented for other tools as well[@b125] and suggests complementarity.[@b109] There are also independent third-party challenges that use unpublished data to assess the ability of methods to predict the functional impact of mutations on proteins, including the critical assessment of genome interpretation (CAGI),[@b126] in which competing groups evaluate genetic variants blindly and have their predictions judged against experimental results on a variety of measures. Most often, no single method outperforms all others in every one of these diverse measures of quality; nevertheless an average rank can be calculated for each method over all of the quality measures. In [Figure 3](#fig03){ref-type="fig"}, we plotted the average ranks of impact predictors in two of the CAGI challenges, where we participated with predictions made by the evolutionary action method (simply Action). The identities of methods other than our own will remain anonymous until the CAGI community publishes comprehensive results.

![Average rank of predictions in two CAGI challenges from the competitions of 2011 and 2012--13. The Cystathionine beta-Synthase (CBS) challenge of 2011 asked predictors to submit the effect of 84 variants in the function of CBS at two different cofactor concentrations,[@b127] which were assessed by nine measures for each concentration (precision, recall, accuracy, harmonic mean F1, Spearman\'s rank, Student\'s *t* test, RMSD, RMSD over z scores, and AUC). The p16 challenge of 2012--13 asked predictors to submit evaluations of how 10 variants of the p16 protein impact its ability to block cell proliferation,[@b128] which were assessed by four measures (AUC, RMSD, Kendall tau, and the number of correct predictions within a range of 10%). A total of 16 participants (color-coded) to one or both challenges submitted one or multiple predictions (20 predictions in 2011 and 22 predictions in 2012--13). The number shown on the vertical axis is an average rank so that in order to have a rank of one, the prediction would need to rank first in all of the evaluation measures that were used. Conversely, the worst a prediction could do would be to be last in every evaluation measure, leading to an average rank equal to the total number of prediction sets in that challenge. Besides Action, only the participants B and C submitted predictions in both challenges. The Evolutionary Action method can be found at: <http://mammoth.bcm.tmc.edu/EvolutionaryAction/>.](pro0023-1650-f3){#fig03}

A way to estimate the popularity of the impact prediction methods is to look at the number of citations per method over years since publication ([Fig. 4](#fig04){ref-type="fig"}). It is clear that certain methods, such as PolyPhen, SIFT, Panther, and Dmutant, have made a lasting impression on the field, and that the methods featured in Table[1](#tbl1){ref-type="table"} have such a large variety in their number of citations that only a logarithmic scale can adequately capture the spread. While this data does not relate to the accuracy of the method or to the applicability of the method to a dataset, it reflects the scientific community\'s perception of the method.

![The total number of citations since each method was published, on a logarithmic scale, according to Scopus[@b2] for methods published before 2014. The methods are colored by the type of information they use as seen in the figure legend. The older and well-established methods of PolyPhen, DMutant, SIFT, and Panther are at the bottom right, in contrast to the new and less-known, methods at the top left, while an abundance of methods are clustered at the center of the graph. Of particular interest is PolyPhen2, which despite its recent release, it is currently the most cited of any method.](pro0023-1650-f4){#fig04}

In summary, one may choose an impact prediction method not only based on its accuracy against a variety of benchmark datasets, but also based on the strengths and limitations of the method in the context of the data at hand. The availability of a structure, the number of available homologs, the convenience of a predictor (web server or local installation), and the ability to submit multiple requests with various formats (vcf files or lists of single amino acid variants) may all affect the preference of a user in practice. In general, the confidence of a prediction is higher when multiple methods are in agreement,[@b129] so studies often use the results from multiple methods to bolster evidence for pathogenicity.[@b42],[@b130],[@b131] To this end, metaservers that compile the results from multiple methods are often time-saving, and several are noted in Supporting Information Table[1](#tbl1){ref-type="table"} along with the original methods.

Applications
============

Typically, SNV impact prediction methods are used to associate amino acid variations to loss of protein function or to risk of diseases. An increasing number of studies use the predicted impact in a variety of applications, and have reported that SNV impact predictions match experimental findings.[@b130],[@b132],[@b133] Such applications include guiding mutagenesis,[@b134],[@b135] identifying disease associated genes in both Mendelian and common diseases,[@b1],[@b136]--[@b139] separating disease-causing variants from linkage disequilibrium variants,[@b140] identifying somatic mutations that drive cancer,[@b65],[@b141],[@b142] and predicting the overall phenotype of an organism.[@b143] These applications highlight the value of SNV impact prediction and the need for further improvement.

Guided mutagenesis
------------------

Predictions of impact may guide mutagenesis studies that aim to uncover functional sites or fine-tune the activity of proteins. Rather than using laborious random mutagenesis and screening to identify functional residues,[@b144],[@b145] site-directed mutagenesis studies[@b146] may be efficiently guided by computational predictions with high rates of success.[@b134],[@b147]--[@b149] Besides selecting strongly deleterious mutations that knock out protein function, often it is desirable to select mutations with an intermediate impact in order to redirect the protein activity.[@b135] Methods like EA, which yield prediction on a continuous scale rather than in binary categories, are appropriate to engineer functional proteins that deviate variably from the wild-type phenotype.[@b135]

nsSNV disease association
-------------------------

nsSNV impact predictors can also aid in untangling disease etiology. Although thousands of associations have been made between nsSNVs and risk of various diseases through GWAS and catalogued in databases like HGMD,[@b120] dbSNP,[@b150] ENSEMBL,[@b151] and UniProt,[@b152] it is often unclear if the nsSNV itself is causative or merely linked to the disease-causing variant. In addition, predisposing nsSNVs usually account for a small fraction of the predicted genetic risk of the complex diseases, a major issue known as "missing" heritability.[@b153]--[@b155] Current theories suggest that common diseases are caused by either common variants with small to modest effects[@b155] or by multiple rare variants.[@b156] In both cases the statistical power is limited by either the linkage disequilibrium or the low population frequency, respectively. nsSNV impact predictions may be used to distinguish the most deleterious nsSNVs from those that are merely in strong linkage disequilibrium with a causative nsSNV,[@b157] or identify deleterious rare nsSNVs that occur on genes that are associated with the disease.[@b158]--[@b160]

Identifying genes that cause diseases
-------------------------------------

Another use of impact predictors is to discover genes associated with genetic disorders.[@b161] In these studies, exome sequencing of unrelated patients with the disorder is conducted under the hypothesis that these exomes will be enriched in mutations that impact the function of a causative gene. The predicted impact of SNVs on protein function may then be used to associate new genes with the studied disorder, such as the genes FRAS1 and FREM2 with Congenital Abnormalities of the Kidney and Urinary Tract (CAKUT),[@b136] the DHODH gene with the Miller syndrome,[@b137] the SLC26A3 gene with Bartter syndrome,[@b1] the TGM6 gene with spinocerebellar ataxias,[@b138] and the VCP gene with Amyotrophic Lateral Sclerosis (ALS).[@b139] With more exome sequencing studies on the way, there is much potential for the widespread use of mutation impact predictors in the clinical setting, given their continuous improvement and almost immediate access to results.

Identifying cancer driver mutations
-----------------------------------

The search for cancer-associated mutations also benefits from predictions of the functional impact. This is a particularly challenging problem, since although cancer-causing mutations may be inherited,[@b162],[@b163] most often they are acquired in somatic cells during tumor development.[@b164],[@b165] The average number of nonsynonymous somatic mutations in a tumor varies widely by cancer type, ranging from as low as four in pediatric rhabdoid cancer to as high as the thousands in colorectal cancer with microsatellite instability.[@b166] Some of these mutations, called drivers, disrupt or further activate the function of proteins to promote cancer, while the rest confer no selective tumor growth advantage and are called passengers.[@b167] Predicting the impact of the variants found by exome sequencing of numerous tumors can help in identifying the genes that are associated with each cancer type.[@b168]--[@b170] Moreover, nsSNV impact can provide clinical information. For example, even when only the TP53 gene is under consideration, predicting the impact of head and neck tumor mutations can stratify patient survival into statistically significant groups.[@b171]

Several nsSNV impact predictors have specifically applied their method to cancer gene discovery, including CanPredict,[@b141] MutationAssessor,[@b65] and SNPs3D.[@b142] CanPredict is a Random Forest classifier, trained on 800 cancerous and 200 non-cancerous mutations, that uses SIFT[@b172] and Pfam-based scores[@b173] to predict impact, and Gene Ontology[@b174] to predict cancer association. This method identified as cancer-associated several novel germline variants that were not present in controls, suggesting they are markers for increased cancer risk.[@b141] The MutationAssessor method predicted the impact of over 10,000 nsSNVs from the COSMIC database,[@b175] which combined with the total number of mutations in a gene and the frequency of each mutation in different tumors, ranked genes for cancer association, recovering known drivers (TP53, PTEN, etc) and suggesting many others.[@b65] The SNPs3D method, consisting of two SVMs based on protein stability and homology respectively, was applied to about 2000 somatic mutations from colorectal and breast cancer to find that virtually all mutations in known cancer genes are predicted to impact protein function and therefore can be detected by nsSNV impact prediction methods.[@b142] These methods produced intriguing novel predictions and may foreshadow wider use of nsSNV impact predictions to elucidate cancer mechanisms.

Predicting the phenotypic behavior of single organisms by integrating the impact of multiple mutations
------------------------------------------------------------------------------------------------------

Although a simple, clinically useful pipeline to reliably annotate all likely phenotypes from a human genome is not yet possible,[@b176] predicting phenotypic variation from genome sequences has made significant advances in model organisms like yeast and has illustrated the centrality of SNV impact prediction to these efforts.[@b143] Genome-scale reverse genetic screens in model organisms have produced thorough, if not complete, sets of genes associated with a variety of phenotypes, aiding the prediction process and allowing for proof-of-concept experiments that apply to human genotype-to-phenotype research.[@b177] One such study used gene sets for 115 phenotypes described by the Saccharomyces Genome Database (SGD)[@b178] and considered how the mutational load in the protein-coding regions of these gene sets varied by yeast strain. The study applied a nsSNV effect predictor, SIFT,[@b172] to determine the probability of damage for non-synonymous mutations. The overall phenotypic effect was calculated with an additive model that combined the SIFT scores with heuristic rules that evaluated premature stop codons and insertions and deletions.[@b178] The actual phenotypic responses of the strains were experimentally determined and they were predicted by the genotype with an ROC AUC value of 0.76.^143^ These results offer hope that in the future SNV impact prediction methods may be similarly applied to integrate the impact of multiple mutations in the human genome as the genes known to be associated with a phenotype become more complete.[@b179]

Future Directions
=================

What are the future challenges the field of SNV impact prediction needs to address?
-----------------------------------------------------------------------------------

### Context-dependence

Despite steady progress in predicting the impact of non-synonymous coding variations, there remains a myriad of challenges for determining how the phenotype of an individual organism is affected by a specific SNV. For example, it is important to know whether and how the phenotypic impact is mitigated by zygosity,[@b180],[@b181] epistasis,[@b182],[@b183] mosaicism,[@b184] gender,[@b185],[@b186] environment,[@b187] epigenetics,[@b188],[@b189] or other unknown factors affecting penetrance and expressivity.[@b190] The recently launched "Resilience Project"[@b191] aims precisely to identify the factors that buffer disease in apparently healthy patients that carry high-risk disease variants.[@b192] As our understanding of these factors expands, we may be able to incorporate this information on a large scale and provide personalized impact predictions.

### Impact of protein function loss on phenotype

A necessary intermediate step in integrating genetic information is to understand the phenotypic association of each protein and its impact on the overall fitness of a species. For example, a SNV in a gene may render the protein nonfunctional, but this loss of protein function can, depending on the role of that protein, be fairly neutral to the organism[@b193] or have observable consequences,[@b194],[@b195] including lethality.[@b196] An additional complication comes from the redundant function of proteins or pathways, resulting in no noticeable phenotypic change when losing the function of only one involved gene.[@b197],[@b198] SNV impact prediction does not yet make any *a priori* assumptions about gene importance, but when the gene involved in the phenotype is well established, it can stratify patient outcomes[@b171] and disease severity.[@b50] Large-scale projects like the NIH Knockout Mouse Project (KOMP)[@b196] and particularly systematic surveys of incidental human knockouts[@b199]--[@b201] promise to shed light on the relative importance of the genes, their role in diseases, and the gene redundancy within a genome, presenting an opportunity for a leap forward in variant prioritization.

### Noncoding regions

Finally, evidence that more than 80% of the human genome may display some functionality[@b202] suggests that there are important limitations in exclusively analyzing exome sequencing data. Consequently, SNV impact prediction is beginning to branch into noncoding regions of the genome. Two recent tools, mrSNP[@b39] and MicroSNiPer[@b40] attempt to identify SNVs in 3\'UTR regions that disrupt miRNA binding, and RNAsnp^41^ predicts the effect of SNVs on the local structure of noncoding RNAs. Future tools will hopefully expand upon this work and may also begin to predict how non-coding SNVs alter methylation patterns and other epigenetic changes.[@b203],[@b204] With the discovery that SNVs in noncoding regions are sometimes disease associated,[@b34]--[@b38] additional methods to deal with these variants will likely arise over time to tackle this problem.

Developing computational methods to estimate the functional impact of SNVs is crucial to understanding the genotype--phenotype relationship, and their importance to research and clinical practice will only grow as sequencing costs plummet further. Already many nsSNV impact prediction methods find broad applications to guided mutagenesis and to the identification of disease causing variants and genes. There are already a plethora of tools available and many new ones complicate the choice of which to use. This review explored current predictors of functional impact in light of the strengths and limitations of the fundamental principles they apply. Factors such as tool availability, public usage, and, most importantly, accuracy must be carefully weighed and understood in the context of the target dataset. In the future, the technical improvements and the availability of new sequence and SNV data should help the computational methods to predict the impact of SNVs with even higher accuracy.
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